The pandemic releases its grip on clinical trials
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Astounding success greets newly public device makers
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
After a big year, biotech flotations have much to do
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Medtech deal-making stands firm in difficult times
It takes more than a pandemic to stop medical device companies merging.
One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
A tale of two Covids for smaller device makers
The pandemic provided the best and worst of times for smid-cap medtechs.
Covid or not, venture financing breaks records
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
